ImmunoPET Using engineered antibody fragments: Fluorine-18 labeled diabodies for same-day imaging

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 669-677

  Olafsen, Tove ^a   Sirk, Shannon J ^a,b   Olma, Sebastian ^a,c   Shen, Clifton K F ^a   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c URENCO UK Limited   (United Kingdom)

Author keywords

Antibody fragment; HER2 imaging; Positron emission tomography; Radiochemistry; Small animal imaging

Indexed keywords

ANTIBODY; ANTIBODY FRAGMENT; CYSDIABODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; DIAGNOSTIC AGENT; FLUORINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; XENOGRAFT; ANIMAL; BREAST TUMOR; CHEMISTRY; IMMUNOLOGY; NUDE MOUSE; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863607660     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0365-8     Document Type: Article

References (36)

1. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14(3):191-7.
2. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2008;40(3):167-81.
3. Nayak TK, Brechbiel MW. Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009;20(5):825-41.
4. Pagani M, Stone-Elander S, Larsson SA. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur J Nucl Med. 1997;24(10):1301-27.
5. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22(6):701-6.
6. Eder M, Knackmuss S, Le Gall F, et al. 68 Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging. 2010;37(7):1397-407.
7. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (singlechain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996;56(13):3055-61.
8. Wu AM, Williams LE, Zieran L, et al. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting. 1999;4:47-58.
9. Williams LE, Liu A, Wu AM, et al. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med Phys. 1995;22(12):2025-7.
10. 18F-labeled T84.66 anticarcinoembryonic antigen diabody. J Nucl Med. 2007;48(2):304-10.
11. Vaidyanathan G, Bigner DD, Zalutsky MR. Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. J Nucl Med. 1992;33(8):1535-41.
12. 18F]fluorobenzoate. Int J Rad Appl Instrum B. 1992;19(3):275-81.
13. 18F]-N-succinimidyl 4-(fluoromethyl) benzoate for protein labeling. Appl Radiat Isot. 1994;45(12):1155-63.
14. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res. 1995;55(22):5323-9.
15. 18F]SFB). J Vis Exp. 2011. doi:10.3791/2755.
16. Olafsen T, Cheung CW, Yazaki PJ, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel. 2004;17(1):21-7.
17. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormoneindependent growth in human breast cancer cells. Oncogene. 1995;10(12):2435-46.
18. Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM. Site-specific, thiol-mediated conjugation of fluorescent probes to cysteinemodified diabodies targeting CD20 or HER2. Bioconjug Chem. 2008;19(12):2527-34.
19. Defrise M, Kinahan PE, Townsend DW, et al. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging. 1997;16(2):145-58.
20. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2(3):131-7.
21. Huang SC, Truong D, Wu HM, et al. An internet-based "kinetic imaging system″ (KIS) for MicroPET. Mol Imaging Biol. 2005;7(5):330-41.
22. 18F- labeling of biomolecules for immuno-positron emission tomography. Mol Imaging. 2011;10(3):168-76.
23. Venisnik KM, Olafsen T, Gambhir SS, Wu AM. Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol Imaging Biol. 2007;9(5):267-77.
24. 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel. 2010;23(4):243-9.
25. Robinson MK, Doss M, Shaller C, et al. Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65(4):1471-8.
26. Aguilar Z, Akita RW, Finn RS, et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene. 1999;18(44):6050-62.
27. Rudnick SI, Adams GP. Affinity and avidity in antibodybased tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155-61.
28. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584(12):2670-80.
29. Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51(6):892-7.
30. Kiesewetter DO, Kramer-Marek G, Ma Y, Capala J. Radiolabeling of HER2 specific Affibody (R) molecule with F-18. J Fluor Chem. 2008;129(9):799-805.
31. 18F] FBEM-Z (HER2:342)-Affibody molecule - A new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35(5):1008-18.
32. 18F-labeled protein scaffold molecules. J Nucl Med. 2008;49(5):804-13.
33. 18F radiolabeling for PET. J Nucl Med. 2009;50(6):991-8.
34. Nwe K, Brechbiel MW. Growing applications of "click chemistry″ for bioconjugation in contemporary biomedical research. Cancer Biother Radiopharm. 2009;24(3):289-302.
35. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A. 2000;97(15):8495-500.
36. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigenspecific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44(12):1962-9.